logo
logo

Imidomics, Inc. Announces Strategic Investment From Drug Discovery And Research Leader Evotec Se

Imidomics, Inc. Announces Strategic Investment From Drug Discovery And Research Leader Evotec Se

02/15/22, 2:00 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgsan rafael
IMIDomics, Inc., a privately held global biotechnology company focused on the discovery and development of new targets and medicines for the treatment of patients with immune-mediated inflammatory diseases (IMIDs), announced today that Evotec SE (FSE: EVT; MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has made an equity investment in the company. In conjunction with the investment, an Evotec representative will join the IMIDomics board of directors. No financial details were disclosed.

Company Info

Company
Imi Domics
Location
san rafael, california, united states
Additional Info
IMIDomics was founded in Barcelona, Spain in 2015 by Dr. Sara Marsal, Head of the Rheumatology Department at the Vall d’Hebron University Hospital, and Dr. Richard M. Myers, President and Scientific Director at the HudsonAlpha Institute for Biotechnology.